C4 Therapeutics (CCCC) Net Margin (2019 - 2026)
C4 Therapeutics' (CCCC) quarterly Net Margin came in at 446.13% in Q1 2026, down 8247.0% year-on-year from 5.48% in Q1 2025, and down 141.32% quarter-over-quarter from 184.87% in Q4 2025.
C4 Therapeutics (CCCC) Net Margin (2019 - 2026) Analysis & Trends
C4 Therapeutics' Net Margin history runs 8 years deep, the most recent figure standing at 446.13% for Q1 2026.
- On a quarterly basis, Net Margin fell 8247.0% year-over-year to 446.13% in Q1 2026; TTM through Mar 2026 was 304.06%, a 4446.0% decrease from a year earlier, with the FY2025 full-year figure at 292.08%, up 388.0% from the prior year.
- Net Margin retreated to 446.13% in Q1 2026 per CCCC's latest filing, from 184.87% in the prior quarter.
- Across five years, Net Margin topped out at 147.56% in Q2 2024 and bottomed at 1348.42% in Q2 2023.
- The 5-year median for Net Margin is 446.13% (2026), against an average of 605.64%.
- Across the five-year window, Net Margin plunged 122492 bps in 2022 and jumped 120086 bps in 2024, its largest moves.
- Year by year, Net Margin stood at 1302.91% in 2022, then increased by 18 bps to 1065.84% in 2023, then jumped by 37 bps to 667.82% in 2024, then soared by 72 bps to 184.87% in 2025, then tumbled by 141 bps to 446.13% in 2026.
- Per Business Quant, the three latest CCCC Net Margin figures stand at 446.13% (Q1 2026), 184.87% (Q4 2025), and 286.43% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | C4 Therapeutics | 460.17 Mn | 224.50 Mn | - | -446.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -446.13% |
| Dec 31, 2025 | -184.87% |
| Sep 30, 2025 | -286.43% |
| Jun 30, 2025 | -402.60% |
| Mar 31, 2025 | -363.66% |
| Dec 31, 2024 | -667.82% |
| Sep 30, 2024 | -160.57% |
| Jun 30, 2024 | -147.56% |
| Mar 31, 2024 | -933.23% |
| Dec 31, 2023 | -1,065.84% |
| Sep 30, 2023 | -244.19% |
| Jun 30, 2023 | -1,348.42% |
| Mar 31, 2023 | -925.25% |
| Dec 31, 2022 | -1,302.91% |
| Sep 30, 2022 | -473.17% |
| Jun 30, 2022 | -930.10% |
| Mar 31, 2022 | -413.12% |
| Dec 31, 2021 | -77.99% |
| Sep 30, 2021 | -290.39% |
| Jun 30, 2021 | -230.86% |